Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

ABSTRACT: The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

PROVIDER: PRJNA997355 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25388300.fastq.gz	Fastqsanger.gz
	SRR25388301.fastq.gz	Fastqsanger.gz
	SRR25388302.fastq.gz	Fastqsanger.gz
	SRR25388303.fastq.gz	Fastqsanger.gz
	SRR25388317.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 104

Similar Datasets

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (RibomethSeq)

Project description:The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (RibomethSeq)

| PRJNA997357 | ENA

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (snoRNA)

Project description:The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (snoRNA)

| PRJNA997356 | ENA

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (snoRNA)

Project description:We combined mRNA, small RNA and ribosome methylation sequencing to investigate snoRNA expression patterns in multiple myeloma and their association with different chromosomal aberrations. We identified snoRNAs dysregulated in molecular subgroups, with SNORD78 being highly expressed in gain1q patients and associated with poor prognosis. Our study shows that the expression of particular snoRNAs and methylation of specific snoRNA-guided rRNA sites are associated with specific chromosome gains, which are common elements in multiple myeloma.

2023-10-16 | GSE237998 | GEO

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations (RibomethSeq)

Project description:We combined mRNA, small RNA and ribosome 2'O-methylation sequencing to investigate snoRNA expression patterns in multiple myeloma and their association with different chromosomal aberrations. We identified snoRNAs dysregulated in molecular subgroups, with SNORD78 being highly expressed in gain1q patients and associated with poor prognosis. Our study shows that the expression of particular snoRNAs and methylation of specific snoRNA-guided rRNA sites are associated with specific chromosome gains, which are common elements in multiple myeloma.

2023-10-16 | GSE237997 | GEO

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations.

Project description: Not available

| S-EPMC10681893 | biostudies-literature

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-10-16 | GSE237999 | GEO

Predict cytogenetic abnormalities with gene expression profiles

Project description:Cytogenetic abnormalities (CA) are important clinical parameters in various types of cancer, including multiple myeloma (MM). We developed a model to predict CA in patients with MM using gene expression profiling (GEP) and validated it by different cytogenetic techniques. The model was shown to have an accuracy up to 0.89. These results provide proof of concept for the hypothesis that GEP could serve as a one-stop data source for clinical molecular diagnosis and/or prognosis.

2012-06-12 | GSE29023 | GEO

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tags (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD038437 | Pride

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tag (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD043580 | Pride

Predict cytogenetic abnormalities with gene expression profiles

2012-06-11 | E-GEOD-29023 | biostudies-arrayexpress